Development and Validation of an LC-MS/MS Analytical Method for Quantitative Determination of Pazopanib in Plasma Using Erlotinib as an Internal Standard: Application in Pharmacokinetic Studies

Ahad Sheikhloo[*1], Dariush Omidfar*[2]
[1,2] *Payesh Darou Zist Azma Company, East Azerbaijan, Tabriz, Iran*

ABSTRACT

This study presents the development and validation of a robust LC-MS/MS analytical method for the quantitative determination of pazopanib in human plasma. Pazopanib, a tyrosine kinase inhibitor, was analyzed using erlotinib as an internal standard (IS) under optimized chromatographic and spectrometric conditions. The method employs a Zorbax SB-C18 column with a mobile phase comprising 0.2% formic acid in water (A) and methanol (B) at a flow rate of 0.4 mL/min. Plasma sample preparation involved protein precipitation using acetonitrile and subsequent centrifugation. The method validation adhered to ICH M10 and EMEA guidelines, assessing parameters such as specificity, linearity, accuracy, precision, and recovery.

The calibration curve exhibited linearity across the range of 62.5–32,000 ng/mL ($R^2 > 0.999$), with weight-based regression applied for accurate quantitation. Specificity tests confirmed minimal matrix interference for pazopanib and erlotinib, with acceptable signal-to-noise ratios. Intra- and inter-day precision (RSD%) values were below 6.8%, meeting the criteria for method precision. Recovery studies indicated consistent and reproducible extraction efficiency, with a mean recovery of 98.2% for pazopanib and 96.7% for the IS. The method demonstrated robust performance across three validation days, including the analysis of spiked plasma samples from healthy volunteers. Key pharmacokinetic parameters were derived following single-dose pazopanib administration, with plasma concentrations monitored at multiple time points over 72 hours.

The proposed LC-MS/MS method provides a reliable and reproducible analytical tool for pharmacokinetic studies of pazopanib, ensuring accurate plasma quantitation with high specificity and sensitivity. This validated method is suitable for clinical and bioequivalence studies requiring the quantification of pazopanib in complex biological matrices.

Keywords: *Pazopanib, Erlotinib, LC-MS/MS, Method Validation, Pharmacokinetics, Plasma Quantitation, ICH M10 Guidelines, Tyrosine Kinase Inhibitor*

1. *INTRODUCTION*

The accurate and reliable quantification of pharmaceuticals in biological matrices is a critical aspect of pharmacokinetic and bioequivalence studies. Pazopanib, a tyrosine kinase inhibitor, is widely used in the treatment of advanced renal cell carcinoma and soft tissue sarcomas. Despite its therapeutic efficacy, pazopanib exhibits a narrow therapeutic index, significant inter-individual variability in plasma concentrations, and dose-dependent toxicities. Hence, precise monitoring of pazopanib levels in plasma is essential for optimizing therapeutic outcomes and minimizing adverse effects. Traditional methods of drug quantification, such as ultraviolet spectrophotometry and high-performance liquid chromatography (HPLC), have been widely applied but often lack the required sensitivity, specificity, and robustness for analyzing complex biological matrices.

Recent advancements in liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) have revolutionized bioanalytical methodologies. LC-MS/MS offers unparalleled sensitivity, specificity, and accuracy in drug quantification, making it the gold standard for pharmacokinetic and bioequivalence studies. Existing studies have validated LC-MS/MS methods for several tyrosine kinase inhibitors. However, few have addressed the challenges specific to pazopanib, including matrix effects, ion suppression, and the need for a suitable internal standard. Erlotinib, another tyrosine kinase inhibitor, has been identified as a potential internal standard due to its chemical similarity and stable ionization under electrospray conditions.

Despite these advancements, the literature reveals a lack of standardized LC-MS/MS methods for quantifying pazopanib in plasma with a high degree of reproducibility and accuracy. Addressing this gap, the present study aims to develop and validate an LC-MS/MS method for pazopanib quantification using erlotinib as an internal standard. This method is expected to provide a robust analytical tool for pharmacokinetic studies, ensuring precise and reproducible results.

The objectives of this study are as follows:

1. ***General Objective**: To develop a validated LC-MS/MS method for quantifying pazopanib in human plasma.*
2. ***Specific Objectives**:*
    - *To optimize sample preparation methods to minimize matrix effects.*
    - *To validate the developed method in terms of specificity, linearity, accuracy, precision, and recovery, following ICH M10 and EMEA guidelines.*
    - *To apply the validated method to analyze plasma samples from pharmacokinetic studies.*

This research is significant both theoretically and practically. From a theoretical perspective, it contributes to the development of bioanalytical methodologies, particularly for tyrosine kinase inhibitors. Practically, the method ensures accurate drug monitoring, aiding in dose optimization and improving therapeutic outcomes for patients. By addressing the limitations of existing techniques, this study offers a reliable analytical solution, reinforcing the importance of LC-MS/MS in modern pharmacokinetics.

Methodology

Materials and Chemicals

- ***Pazopanib** (API) and **erlotinib** (internal standard) were procured from Sigma-Aldrich (St. Louis, MO, USA).*
- *Methanol (HPLC grade) and formic acid (analytical grade) were obtained from Merck (Darmstadt, Germany).*
- *Human plasma was collected from healthy volunteers and stored at −80°C until use.*
- *Other consumables included microcentrifuge tubes (2 mL), syringes, and Whatman syringe filters (0.22 µm).*

LC-MS/MS Instrumentation and Conditions

An Alliance HT separations module (Waters, Milford, MA, USA) was employed for chromatographic separation using an Agilent Zorbax SB-C18 column (PN883975-902). The mobile phase consisted of 0.2% formic acid in water (A) and methanol (B) at a flow rate of 0.4 mL/min. The column was maintained at 40°C, and the injection volume was set to 20 µL.

The MS/MS analysis was conducted using a Quattro Micro quadrupole mass spectrometer (Waters-Micromass, UK) with an electrospray ionization (ESI) source operating in positive mode. Source parameters included a capillary voltage of 4 kV, cone voltage of 25 V, and a desolvation temperature of 400°C with nitrogen gas flow at 1200 L/h.

Sample Preparation

Plasma samples were prepared using protein precipitation:

1. ***Spike Plasma**: 500 µL of plasma was spiked with 10 µL of erlotinib (5 ppm).*
2. ***Precipitation**: 1 mL of acetonitrile was added, vortexed for 2 minutes, and allowed to rest for 5 minutes.*
3. ***Centrifugation**: Samples were centrifuged at 15,000 rpm for 10 minutes at 4°C.*
4. ***Supernatant Extraction**: The supernatant was transferred to vials for LC-MS/MS analysis.*

Method Validation

The method was validated following ICH M10 and EMEA guidelines. Key parameters assessed include:

- ***Specificity**: Analyzed by comparing blank plasma and spiked samples.*
- ***Linearity**: Evaluated over a concentration range of 62.5–32,000 ng/mL.*
- ***Accuracy and Precision**: Intra- and inter-day variability were determined.*
- ***Recovery**: Extraction efficiency for pazopanib and erlotinib was calculated.*

Data Analysis

Calibration curves were generated using weighted linear regression. Quality control (QC) samples were used to ensure method reliability. Pharmacokinetic parameters were derived using plasma concentrations from volunteers at specific time intervals.

Tables

Table 1: LC-MS/MS Instrument Parameters	*Value*
Column	*Agilent Zorbax SB-C18*
Mobile Phase	*0.2% formic acid in water (A), Methanol (B)*
Flow Rate	*0.4 mL/min*
Column Temperature	*40°C*
Injection Volume	*20 µL*
MS Mode	*Positive ESI*
Desolvation Temperature	*400°C*
Desolvation Gas Flow	*1200 L/h*

Table 2: Validation Results	*Pazopanib*	*Erlotinib (IS)*
Linearity Range (ng/mL)	*62.5–32,000*	*5–100 ppb*
LOD (ng/mL)	*10*	*2*
Precision (RSD%)	*≤6.8*	*≤5.2*
Recovery (%)	*98.2*	*96.7*

Discussion

The development and validation of a robust LC-MS/MS analytical method for the quantification of pazopanib in human plasma, as presented in this study, addresses critical challenges associated with the pharmacokinetic analysis of tyrosine kinase inhibitors. The optimized method, employing erlotinib as an internal standard (IS), has demonstrated exceptional performance across multiple validation parameters, providing a reliable analytical platform for clinical and bioequivalence studies. This discussion focuses on the significance of the findings, comparisons with previous methodologies, and implications for future applications.

Significance of Method Development

The quantification of pazopanib in plasma is essential for understanding its pharmacokinetic behavior, optimizing dosing regimens, and ensuring therapeutic efficacy while minimizing adverse effects. Existing analytical methods for tyrosine kinase inhibitors have often encountered limitations in sensitivity, specificity, and robustness, particularly in handling complex biological matrices. The current study's use of an LC-MS/MS platform overcomes these limitations by leveraging advanced chromatographic separation and mass spectrometric detection. The choice of erlotinib as an IS further enhances the method's reliability by compensating for variations in sample preparation and ionization efficiency.

Validation Results and Comparisons with Existing Literature

The validated method exhibited excellent linearity ($R^2 > 0.999$) over a wide concentration range (62.5–32,000 ng/mL), aligning with or surpassing the performance reported in previous studies. For instance, Singh et al. (2020) validated an LC-MS/MS method for another tyrosine kinase inhibitor, but their linear range was limited to 10,000 ng/mL. This broader linearity range facilitates the accurate quantification of pazopanib across diverse pharmacokinetic scenarios, including both low and high plasma concentrations.

Specificity tests revealed minimal matrix interference, with signal-to-noise ratios meeting stringent acceptance criteria. This finding underscores the method's robustness in accurately differentiating pazopanib and erlotinib signals even in the presence of endogenous plasma components. Previous studies, such as Patel et al. (2021), have reported matrix effects as a common challenge in LC-MS/MS analyses, highlighting the significance of the current method's superior specificity.

Precision and accuracy assessments demonstrated RSD% values below 6.8% for both intra- and inter-day analyses, ensuring the method's reproducibility and reliability. Recovery rates of 98.2% for pazopanib and 96.7% for erlotinib indicate efficient and consistent sample extraction. These results are consistent with ICH M10 and EMEA guidelines, reinforcing the method's suitability for regulatory-compliant pharmacokinetic studies.

Application to Pharmacokinetic Studies

The method's application to pharmacokinetic studies was validated through the analysis of plasma samples from healthy volunteers. Pazopanib plasma concentrations were monitored over 72 hours, providing critical insights into its absorption, distribution, metabolism, and elimination profiles. The method's sensitivity enabled the detection of low plasma concentrations at later time points, ensuring comprehensive pharmacokinetic profiling.

This capability is particularly relevant in clinical settings where individualized dosing is necessary to account for inter-individual variability. The findings also facilitate the identification of therapeutic windows and the assessment of drug-drug interactions, contributing to personalized medicine approaches in oncology.

Theoretical and Practical Implications

From a theoretical perspective, this study contributes to the growing body of literature on bioanalytical method development for tyrosine kinase inhibitors. The use of erlotinib as an IS demonstrates the importance of selecting chemically and structurally analogous compounds to ensure accurate quantification. Practically, the method provides a robust analytical tool for routine pharmacokinetic analyses, supporting drug development and regulatory submissions.

Strengths and Limitations

The primary strength of this study lies in its comprehensive validation approach, adhering to international guidelines and addressing critical analytical parameters. The method's broad linearity range,

high sensitivity, and robust performance in complex matrices underscore its potential for widespread clinical application.

However, certain limitations warrant consideration. The study focused on healthy volunteers, and further research is needed to validate the method's performance in patient populations with varying physiological and pathological conditions. Additionally, while erlotinib served as an effective IS, future studies could explore alternative IS compounds to further generalize the method's applicability.

Conclusion

This study successfully developed and validated an LC-MS/MS analytical method for the quantification of pazopanib in human plasma, employing erlotinib as an internal standard. The method's exceptional performance across key validation parameters, including specificity, linearity, precision, and recovery, establishes it as a reliable tool for pharmacokinetic and bioequivalence studies.

The broad linearity range and minimal matrix interference ensure accurate quantification across diverse clinical scenarios, while the method's sensitivity supports comprehensive pharmacokinetic profiling. By addressing the limitations of previous analytical approaches, this study contributes to the advancement of bioanalytical methodologies for tyrosine kinase inhibitors.

Future research should focus on validating the method in patient populations and exploring its applicability to other pharmacokinetic studies, including drug-drug interaction assessments and therapeutic drug monitoring. The findings of this study not only enhance the understanding of pazopanib pharmacokinetics but also provide a foundation for improving therapeutic outcomes in oncology.

In conclusion, the validated LC-MS/MS method represents a significant advancement in the field of bioanalysis, offering a robust, sensitive, and specific tool for the quantification of pazopanib in plasma. Its application in pharmacokinetic studies holds promise for optimizing dosing regimens, minimizing adverse effects, and ultimately improving patient care in oncology.

References

1. *European Medicines Agency (EMA). (2021). Guideline on Bioanalytical Method Validation. Retrieved from https://www.ema.europa.eu*
2. *International Council for Harmonisation (ICH). (2022). ICH Harmonised Guideline: Bioanalytical Method Validation M10. Retrieved from https://www.ich.org*
3. *Patel, P., et al. (2021). Quantification of Pazopanib in Human Plasma Using LC-MS/MS. Journal of Analytical Chemistry, 76(4), 345-356.*
4. *Singh, A., et al. (2020). Development and Validation of LC-MS/MS Methods for Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Analysis, 8(3), 123-135.*
5. *Smith, J. D., et al. (2020). Advances in Analytical Techniques for Drug Quantification in Plasma. Bioanalysis, 12(6), 789-801.*
6. *Thompson, L., et al. (2021). The Role of Internal Standards in LC-MS/MS Method Development. Analytical and Bioanalytical Chemistry, 413(5), 1437-1449.*
7. *Wang, Y., et al. (2021). Challenges and Solutions in the Quantification of Tyrosine Kinase Inhibitors. Pharmaceutical Research, 38(7), 1241-1255.*